CARD GUARD AG, CH0012815459

LifeWatch AG: LifeWatch AG und BioTelemetry, Inc.

08.05.2017 - 15:25:24

LifeWatch AG: LifeWatch AG und BioTelemetry, Inc. erhalten kartellrechtliche Freigabe

^

EQS Group-Ad-hoc: LifeWatch AG / Schlagwort(e): Übernahmeangebot

LifeWatch AG: LifeWatch AG und BioTelemetry, Inc. erhalten kartellrechtliche

Freigabe

08.05.2017 / 15:22 CET/CEST

Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR

LifeWatch AG und BioTelemetry, Inc. erhalten kartellrechtliche Freigabe

Zug/Schweiz und Malvern, PA - 8. Mai 2017 - LifeWatch AG (SIX Swiss

Exchange:LIFE) und BioTelemetry, Inc. (NASDAQ:BEAT) geben, wirksam per 5.

Mai 2017, die vorzeitige Beendigung der geltenden Wartezeit unter dem

Hart-Scott-Rodino Antitrust Improvements Act von 1976 ("HSR") in Hinsicht

auf das zuvor angekündigte Übernahmeangebot von BioTelemetry für alle

ausstehenden Aktien der LifeWatch AG bekannt. Diese Bewilligung untersteht

keinen Bedingungen oder Forderungen, weder für LifeWatch noch für

BioTelemetry oder eine ihrer Tochtergesellschaften. LifeWatch und

BioTelemetry erhielten ausserdem alle notwendigen kartellrechtlichen

Bewilligungen von der Mazedonischen Kommission (Macedonian Commission),

welche aufgrund der Aktivitäten von LifeWatch Mazedonien, eine

hundertprozentige Tochtergesellschaft der LifeWatch AG, notwendig waren.

Mit dem Ablauf der HSR-Wartefrist wird eine der Konditionen des ausstehenden

Übernahmeangebots, welches - wie im Angebotsprospekt von BioTelemetry per

24. April 2017 beschrieben - nach wie vor von anderen Konditionen abhängt,

erfüllt. Vorbehaltlich der Erfüllung der anderen Konditionen erwartet

BioTelemetry den Abschluss der Übernahme im dritten Quartal 2017.

Gemäss aktuellem Zeitplan beginnt die Hauptangebotsfrist am 10. Mai 2017 und

endet voraussichtlich am 23. Mai 2017, unter Vorbehalt einer Verlängerung

der Angebotsfrist.

Für Rückfragen:

LifeWatch AG, Andrew Moore, CFO

c/o Communicators AG , Ralph Spillmann

Mobile: +41 79 514 64 84

E-Mail: investor-relations@lifewatch.com

Zu LifeWatch AG

LifeWatch AG, mit Hauptsitz in Zug und Kotierung an der SIX Swiss Exchange

(LIFE) in der Schweiz, ist ein führender Anbieter von ferngesteuerten

diagnostischen "Digital Health" Dienstleistungen. Die Dienstleistungen von

LifeWatch liefern den Ärzten wichtige Informationen zur angemessenen

Behandlung ihrer Patienten mit dem Ziel, die Behandlung zu optimieren.

LifeWatch AG verfügt über operative Tochtergesellschaften in den USA, der

Schweiz, Israel und der Türkei und ist die Muttergesellschaft von LifeWatch

Services, Inc., LifeWatch Technologies Ltd. und LifeWatch Turkey Holding AG

(Joint Venture). LifeWatch Services, Inc. ist ein führender US-Anbieter für

Herzüberwachungsdienstleistungen. LifeWatch Technologies Ltd. in Israel ist

ein führender Hersteller von Digital-Health-Produkten. LifeWatch Salk

Hizmetlerine A.S. ist die operative Tochtergesellschaft der LifeWatch Turkey

Holding AG und Anbieter von Herzüberwachungsdienstleistungen in der Türkei.

Für weitere Informationen: siehe www.lifewatch.com.

E-Mail Alert: Um regelmässig die neusten Informationen zu LifeWatch zu

erhalten und Unterlagen anzufordern, registrieren Sie sich bitte unter

https://www.lifewatch.com/Investor-Relations/Alert-Service.html.

Zu BioTelemetry

BioTelemetry, Inc., früher als CardioNet bekannt, ist ein führendes

Unternehmen im Bereich kabelloser Medizinaltechnologie. Der Fokus liegt auf

der Bereitstellung von Gesundheitsdaten zur Verbesserung der Lebensqualität

sowie zur Reduktion der Gesundheitskosten. Das Unternehmen bietet zurzeit

Herzüberwachungs-Dienstleistungen an und produziert Geräte mit einem

primären Fokus auf die Herzüberwachung sowie zentralisierte Dienstleistungen

für Herzlaboratorien.

Für weitere Informationen: siehe www.biotelinc.com.

Cautionary Statement Regarding Forward-Looking Statements

This document includes certain forward-looking statements regarding, among

other things, statements about BioTelemetry's proposed acquisition of

LifeWatch AG, including the timing and success of the tender offer. These

statements may be identified by words such as "expect," "anticipate,"

"estimate," "intend," "plan," "believe," "promises", "projects," and other

words and terms of similar meaning. Such forward-looking statements are

based on current expectations and involve inherent risks and uncertainties,

including important factors that could delay, divert, or change any of these

expectations, and could cause actual outcomes and results to differ

materially from current expectations. Factors that may materially affect

such forward-looking statements include: BioTelemetry's ability to

successfully complete the tender offer for LifeWatch's shares and the

failure of any of the conditions to BioTelemetry's tender offer to be

satisfied. For further details and a discussion of these and other risks and

uncertainties, please see BioTelemetry's public filings with the Securities

and Exchange Commission, including the company's latest periodic reports on

Form 10-K and 10-Q respectively, LifeWatch's past press releases, reports

and other information posted on LifeWatch's website. Readers are cautioned

not to put undue reliance on forward-looking statements, which reflect only

opinions as of the date of this press release. BioTelemetry and LifeWatch do

not undertake, and specifically disclaim, any obligation to publicly update

or amend any forward-looking statement, whether as a result of new

information, future events, or otherwise.

OFFER RESTRICTIONS

The public tender offer described in the offer documents (the "Offer") is

not being and will not be made, directly or indirectly, in any country or

jurisdiction in which it would be considered unlawful or otherwise violate

any applicable laws or regulations, or which would require BioTelemetry or

any of its subsidiaries to change or amend the terms or conditions of the

Offer in any material way, to make an additional filing with any

governmental, regulatory or other authority or take additional action in

relation to the Offer. It is not intended to extend the Offer to any such

country or jurisdiction. Any such documents relating to the Offer must

neither be distributed in any such country or jurisdiction nor be sent into

such country or jurisdiction, and must not be used for the purpose of

soliciting the purchase of securities of LifeWatch by any person or entity

resident or incorporated in any such country or jurisdiction.

Notice to U.S. Persons Holding LifeWatch Shares

The Offer is made for the securities of a non-U.S. company. The Offer is

subject to the disclosure and procedural requirements of Switzerland, which

are different from those of the United States (the "U.S.").

The Offer may not be accepted before expiration of a cooling-off period of

ten (10) trading days, which will run from April 25, 2017 through May 9,

2017, unless extended by the Swiss Takeover Board.

According to the laws of Switzerland, LifeWatch shares tendered into the

Offer may be withdrawn after they are tendered until the expiration of the

main offer period.

BioTelemetry and any of its subsidiaries and any advisor, broker or

financial institution acting as an agent or for the account or benefit of

BioTelemetry or the Offeror may, subject to applicable Swiss securities

laws, rules and regulations, make certain purchases of, or arrangements to

purchase, LifeWatch shares from shareholders of LifeWatch who are willing to

sell their LifeWatch shares outside the Offer from time to time, including

purchases in the open market at prevailing prices or in private transactions

at negotiated prices. The Offeror will disclose promptly any information

regarding such purchases of LifeWatch shares in Switzerland through the

electronic media and/or the stock exchange and in the U.S. by means of a

press release, if and to the extent required under applicable laws, rules

and regulations in Switzerland.

It may be difficult for U.S. holders to enforce their rights and any claim

arising out of U.S. federal securities laws, since LifeWatch is located in a

non-U.S. jurisdiction, and some or all of its officers and directors may be

residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a

non-U.S. company or its officers or directors in a non-U.S. court for

violations of the U.S. securities laws. Further, it may be difficult to

compel a non-U.S. company and its affiliates to subject themselves to a U.S.

court's judgment.

The receipt of cash and stock consideration in the Offer by a U.S.

shareholder will generally be a taxable transaction for U.S. federal, state

and local income tax purposes. Each U.S. shareholder is urged to consult his

independent professional adviser immediately regarding the tax consequences

of acceptance of the Offer.

Securities may not be offered or sold in the U.S. absent registration or an

exemption from registration under the U.S. Securities Act. It is expected

that the Offer will be subject to a Tier I exemption pursuant to Rule

14d-1(c) of the U.S. Securities Exchange Act of 1934, as amended, and that

the issuance of BioTelemetry Common Stock in connection therewith will be

exempt from registration under the U.S. Securities Act of 1933, as amended,

pursuant to Rule 802 thereof.

Neither the Securities and Exchange Commission nor any securities commission

of any State of the U.S. has (a) approved or disapproved of the Offer, (b)

passed upon the merits or fairness of the Offer, or (c) passed upon the

adequacy or accuracy of the disclosure in the pre-announcement. Any

representation to the contrary is a criminal offense in the U.S.

Im Zweifelsfall gilt die englische Originalmeldung.

Zusatzmaterial zur Meldung:

Dokument: http://n.eqs.com/c/fncls.ssp?u=VSOITGVSGT

Dokumenttitel: 20170508_Antitrust Clearance_DE

Ende der Ad-hoc-Mitteilung

Sprache: Deutsch

Unternehmen: LifeWatch AG

Baarerstrasse 139

6300 Zug

Schweiz

Telefon: +41 41 728 67 78

Internet: www.lifewatch.com

ISIN: CH0012815459

Valorennummer: 811189

Börsen: Freiverkehr in Berlin, Stuttgart; Open Market in

Frankfurt; SIX Swiss Exchange

Ende der Mitteilung EQS Group News-Service

571029 08.05.2017 CET/CEST

°

@ dpa.de